\-\ Texto\\:\\ \ \(0\)\
\-\ non\\-contributory\ \(73\)\
\-\ multiple\\ pumonary\\ nodules\\ which\\ show\\ increased\\ metabolic\\ activity\\ on\\ pet\\.\ \(0\)\
\-\ uterine\\ leiomyosarcom\\ with\\ pulmonary\\ metastasis\ \(0\)\
\-\ thromboemboli\\ with\\ organizing\\ infarcts\ \(0\)\
\-\ septic\\ emboli\ \(22\)\
\-\ wegener\\ granulomatosis\ \(0\)\
\-\ malignancy\\:\ \(1\)\
\-\ \\ \\ \\ metastases\\(breast\\,renal\\,gi\\,uterus\\,ovary\\,sarcoma\\)\\,lymphoma\\,\ \(0\)\
\-\ \\ \\ \\ multiple\\ primary\\ bronchgenic\\ ca\ \(0\)\
\-\ benign\\:\ \(2\)\
\-\ \\ \\ \\ hamartoma\\,benign\\ mets\\ leimyoma\\ av\\ malformation\\,\\ amyloidosis\ \(0\)\
\-\ history\\ of\\ large\\ symptomatic\\ uterine\\ fibroids\\.patient\\ elected\\ for\\ uterine\\ artery\\ embolization\\ \\(uae\\)\\ as\\ treatment\\ modality\\.\\ 18\\ months\\ after\\ uae\\ develop\\ sob\\/cough\\.\ \(0\)\
\-\ uterine\\ leiomysarcoma\\ can\\ arise\\ independent\\ of\\ leiomyoma\\(fibroids\\)as\\ well\\ as\\ occuring\\ with\\ sarcomatous\\ transformation\\ of\\ preexisitng\\ leiomyoma\\(reported\\ between\\ 1\\%\\-02\\%\\ of\\ pathology\\ specimens\\ from\\ uteruses\\ removed\\ for\\ symptomatic\\ leiomyomas\\)\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ uterine\\:\\ 0\\.36099248386460997\ \(0\)\
\-\ uae\\:\\ 0\\.29536072634559773\ \(0\)\
\-\ fibroids\\:\\ 0\\.21849072216891205\ \(0\)\
\-\ leiomyoma\\:\\ 0\\.20071821343371543\ \(0\)\
\-\ leiomyosarcom\\:\\ 0\\.15454956815139687\ \(0\)\
\-\ bronchgenic\\:\\ 0\\.15454956815139687\ \(0\)\
\-\ leiomysarcoma\\:\\ 0\\.15454956815139687\ \(0\)\
\-\ preexisitng\\:\\ 0\\.15454956815139687\ \(0\)\
\-\ symptomatic\\:\\ 0\\.14862210727734848\ \(0\)\
\-\ pumonary\\:\\ 0\\.14768036317279887\ \(0\)\
\-\ leimyoma\\:\\ 0\\.14768036317279887\ \(0\)\
\-\ uteruses\\:\\ 0\\.14768036317279887\ \(0\)\
\-\ thromboemboli\\:\\ 0\\.1390261883799516\ \(0\)\
\-\ independent\\:\\ 0\\.13593737969927797\ \(0\)\
\-\ benign\\:\\ 0\\.13277131953790938\ \(0\)\
\-\ leiomyomas\\:\\ 0\\.12906817472067994\ \(0\)\
\-\ organizing\\:\\ 0\\.1272832049064307\ \(0\)\
\-\ sarcomatous\\:\\ 0\\.1272832049064307\ \(0\)\
\-\ occuring\\:\\ 0\\.12158284569736684\ \(0\)\
\-\ elected\\:\\ 0\\.11932061773083413\ \(0\)\
\-\ specimens\\:\\ 0\\.11732519124715904\ \(0\)\
\-\ as\\:\\ 0\\.11647203477914449\ \(0\)\
\-\ wegener\\:\\ 0\\.10811550622746643\ \(0\)\
\-\ av\\:\\ 0\\.10757763425731322\ \(0\)\
\-\ granulomatosis\\:\\ 0\\.1065505595579633\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.1065505595579633\ \(0\)\
\-\ mets\\:\\ 0\\.09935238222298473\ \(0\)\
\-\ transformation\\:\\ 0\\.09871300279504014\ \(0\)\
\-\ modality\\:\\ 0\\.09557198592506036\ \(0\)\
\-\ hamartoma\\:\\ 0\\.09505856651246831\ \(0\)\
\-\ emboli\\:\\ 0\\.09480757608444239\ \(0\)\
\-\ infarcts\\:\\ 0\\.09456024988137343\ \(0\)\
\-\ ovary\\:\\ 0\\.09456024988137343\ \(0\)\
\-\ multiple\\:\\ 0\\.09453816997156275\ \(0\)\
\-\ septic\\:\\ 0\\.09184379781644213\ \(0\)\
\-\ pet\\:\\ 0\\.08950331777534751\ \(0\)\
\-\ develop\\:\\ 0\\.08896544580519432\ \(0\)\
\-\ arise\\:\\ 0\\.08844412639524647\ \(0\)\
\-\ metabolic\\:\\ 0\\.08760939874946382\ \(0\)\
\-\ uterus\\:\\ 0\\.08476671852403987\ \(0\)\
\-\ embolization\\:\\ 0\\.08422454284650356\ \(0\)\
\-\ ca\\:\\ 0\\.08245291808534487\ \(0\)\
\-\ removed\\:\\ 0\\.0820962408265963\ \(0\)\
\-\ gi\\:\\ 0\\.08118025861727222\ \(0\)\
\-\ sarcoma\\:\\ 0\\.08106916612724638\ \(0\)\
\-\ metastases\\:\\ 0\\.0781286432424756\ \(0\)\
\-\ nodules\\:\\ 0\\.07678692307472156\ \(0\)\
\-\ pathology\\:\\ 0\\.0758664152759429\ \(0\)\
\-\ of\\:\\ 0\\.0756486534792497\ \(0\)\
\-\ malformation\\:\\ 0\\.07453544823074758\ \(0\)\
\-\ 18\\:\\ 0\\.07323160936432323\ \(0\)\
\-\ malignancy\\:\\ 0\\.0723486838367505\ \(0\)\
\-\ activity\\:\\ 0\\.07095196078543548\ \(0\)\
\-\ metastasis\\:\\ 0\\.07083051550535882\ \(0\)\
\-\ breast\\:\\ 0\\.070177695740317\ \(0\)\
\-\ reported\\:\\ 0\\.069605291833472\ \(0\)\
\-\ between\\:\\ 0\\.06279246475722665\ \(0\)\
\-\ show\\:\\ 0\\.061349759998370605\ \(0\)\
\-\ renal\\:\\ 0\\.06018091422883645\ \(0\)\
\-\ artery\\:\\ 0\\.060020329670852635\ \(0\)\
\-\ primary\\:\\ 0\\.059423624179885566\ \(0\)\
\-\ pulmonary\\:\\ 0\\.058906981008346196\ \(0\)\
\-\ for\\:\\ 0\\.05858212796126605\ \(0\)\
\-\ lymphoma\\:\\ 0\\.05755553951035034\ \(0\)\
\-\ with\\:\\ 0\\.0567703901487581\ \(0\)\
\-\ months\\:\\ 0\\.05625272427125009\ \(0\)\
\-\ increased\\:\\ 0\\.05225871215942575\ \(0\)\
\-\ can\\:\\ 0\\.05071399420160656\ \(0\)\
\-\ large\\:\\ 0\\.04842180362984975\ \(0\)\
\-\ after\\:\\ 0\\.046882002994038115\ \(0\)\
\-\ well\\:\\ 0\\.04679391851126127\ \(0\)\
\-\ treatment\\:\\ 0\\.046035108255563714\ \(0\)\
\-\ which\\:\\ 0\\.04394350206760047\ \(0\)\
\-\ from\\:\\ 0\\.0383816013443949\ \(0\)\
\-\ history\\:\\ 0\\.036922353971666357\ \(0\)\
\-\ on\\:\\ 0\\.029187159674425457\ \(0\)\
